Aug 08, 2026 — Digital Edition
Gerald Ideas
Independent Journalism & Insight
Feature

Why Are Prostate Cancer Preclinical Models Hard to Develop · creative inspiration

Why Are Prostate Cancer Preclinical Models Hard to Develop

Why Are Prostate Cancer Preclinical Models Hard to Develop
Why Are Prostate Cancer Preclinical Models Hard to Develop

Model panels are being generated, but these tend to be at much lower numbers then for other cancer indications. What Next for Preclinical Prostate Cancer Research? Patient-derived models , and newer technologies such as organoids, continue to offer more patient relevant tools by capturing more of prostate cancer's complexity.

PDF Downregulation of CAMK2N1 due to DNA Hypermethylation Mediated
PDF Downregulation of CAMK2N1 due to DNA Hypermethylation Mediated

The incidence and mortality from prostate cancer (PCa) are on the rise which poses a major public health concern worldwide. In this narrative review, we have summarized the characteristics of major in vitro and in vivo PCa models including their utility in developing treatment strategies. Androgens, particularly, testosterone and dihydrotestosterone (DHT) activate the androgen receptor (AR ...

The Current State of Preclinical Prostate Cancer Animal Models

Beefing up Prostate Cancer Therapy with Performance Enhancing Anti
Beefing up Prostate Cancer Therapy with Performance Enhancing Anti

Prostate cancer continues to be a major cause of morbidity and mortality in men around the world. The field of prostate cancer research continues to be hindered by the lack of relevant preclinical models to study tumorigenesis and to further development ...

2. Prostate Cancer Modelling: From Traditional to Emerging Models The biological and clinical complexity of PCa has driven the development of diverse experimental models capable of reproducing specific aspects of the disease.

What Are the 4 Stages of Prostate Cancer Explained
What Are the 4 Stages of Prostate Cancer Explained

In Vivo Prostate Cancer Modelling

Prostate cancer (PCa) remains one of the most prevalent malignancies in men and a leading cause of cancer -related mortality worldwide. Over the last century, PCa modelling has evolved from basic cell-based to more complex systems. Despite this, the clinical translation of research findings is limited by the constraints of current preclinical models . In this review, rat and zebrafish models are ...

Prostate cancer depends on the hormonal environment for growth. In this Review, the authors describe how this hormonal dependency can be studied in preclinical models . Advantages and limitations ...

Cross talk between genetic and epigenetic mechanisms driving prostate
Cross talk between genetic and epigenetic mechanisms driving prostate

Modeling prostate cancer

In this review, we have critically evaluated the commonly used preclinical models of prostate cancer with respect to their capability of recapitulating the key genomic alterations, histopathological features and bone metastatic potential of human prostate tumors.

Integration of prostate cancer endocrinology, including intracrinology, in preclinical models is essential to understand tumour biology and to facilitate transition from basic science to clinical ...

Stage 2 Prostate Cancer Treatment Options
Stage 2 Prostate Cancer Treatment Options

PDF Preclinical and Clinical Research Models of Prostate Cancer

Overall, PCa research models can be classified into preclinical and clinical models , where preclinical models are higher in both number and frequency of use. Preclinical models include primary and secondary cell lines, patient-derived or cell-line derived xenografts, transgenic mouse, knockout mouse, and cancer -related inflammation models .

Downregulation of SEPTIN5 inhibits prostate cancer progression
Downregulation of SEPTIN5 inhibits prostate cancer progression
Frontiers
Frontiers
Brucine Suppresses Malignant Progression of Prostate Cancer
Brucine Suppresses Malignant Progression of Prostate Cancer
Frontiers
Frontiers
Downregulation of SEPTIN5 inhibits prostate cancer progression
Downregulation of SEPTIN5 inhibits prostate cancer progression
Prostate Cancer Disease Process NYDXRF
Prostate Cancer Disease Process NYDXRF
Pentamidine causes mtDNA reduction in prostate cancer cells A GSEA
Pentamidine causes mtDNA reduction in prostate cancer cells A GSEA

This review highlights how these models enable patient-specific drug screening, biomarker discovery, and mechanistic studies, bridging the gap between preclinical research and personalized treatment strategies—particularly for advanced or treatment-resistant prostate cancer .